Annals of Oncology· @Annals_Oncology · X·· 22 小时前评分70
正文 · 机器翻译
📢 #ESMO26 同期论文 - Pembrolizumab 联合化疗用于 HR+/HER2− PD-L1‒阳性晚期乳腺癌：3 期 KEYNOTE-B49 研究的最终分析。
🔗https://tinyurl.com/3xrc9ycw
@hoperugo
174 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Annals of Oncology · x.com